AbstractAntibody B4e8 exhibits modest cross-neutralizing activity, with preference for HIV subtype B. This preference might be explained by B4e8׳s extensive interaction with Arg315, which occurs at the center of most subtype B V3 sequences but is replaced by Gln in subtype C. The extent to which B4e8׳s ability to neutralize subtype C strains is hindered by Gln315 and/or other factors, e.g. epitope masking, is unclear. We confirmed here that an Arg315-to-Gln substitution in a subtype B virus abrogates B4e8 neutralizing activity. Conversely, B4e8-resistant subtype C viruses were rendered sensitive upon Gln 315-to-Arg substitution. V2 region swapping between B4e8-sensitive and- resistant subtype C strains revealed a role for V2 in limiting B4e...
Epitopes that drive the initial autologous neutralizing antibody response in HIV-1-infected individu...
The early autologous neutralizing antibody response in human immunodeficiency virus type 1 (HIV-1) s...
The early autologous neutralizing antibody response in human immunodeficiency virus type 1 (HIV-1) s...
AbstractAntibody B4e8 exhibits modest cross-neutralizing activity, with preference for HIV subtype B...
The limited neutralizing activity of V3 antibodies is typically attributed to V3 masking. While rela...
AbstractThe identification of cross-neutralizing antibodies to HIV-1 is important for designing anti...
AbstractIdentification of vulnerability in the HIV-1 envelope (Env) will aid in Env-based vaccine de...
International audienceBroadly neutralizing antibodies (bnAbs) directed against the mannose-patch on ...
Background: Broadly neutralizing antibodies (bnAbs) directed against the mannose-patch on the HIV en...
AbstractTo better understand the limits of antigenic reactivity and epitope accessibility of the V3 ...
AbstractThe V3 region of the HIV-1 envelope (Env) glycoprotein gp120 is a key functional domain yet ...
SummaryThe third variable (V3) loop and the CD4 binding site (CD4bs) of the HIV-1 envelope are frequ...
The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the "principal neutrali...
<div><p>Primary isolates of HIV-1 resist neutralization by most antibodies to the CD4 binding site (...
Neutralizing antibodies that recognize the human immunodeficiency virus gpl20 exterior envelope glyc...
Epitopes that drive the initial autologous neutralizing antibody response in HIV-1-infected individu...
The early autologous neutralizing antibody response in human immunodeficiency virus type 1 (HIV-1) s...
The early autologous neutralizing antibody response in human immunodeficiency virus type 1 (HIV-1) s...
AbstractAntibody B4e8 exhibits modest cross-neutralizing activity, with preference for HIV subtype B...
The limited neutralizing activity of V3 antibodies is typically attributed to V3 masking. While rela...
AbstractThe identification of cross-neutralizing antibodies to HIV-1 is important for designing anti...
AbstractIdentification of vulnerability in the HIV-1 envelope (Env) will aid in Env-based vaccine de...
International audienceBroadly neutralizing antibodies (bnAbs) directed against the mannose-patch on ...
Background: Broadly neutralizing antibodies (bnAbs) directed against the mannose-patch on the HIV en...
AbstractTo better understand the limits of antigenic reactivity and epitope accessibility of the V3 ...
AbstractThe V3 region of the HIV-1 envelope (Env) glycoprotein gp120 is a key functional domain yet ...
SummaryThe third variable (V3) loop and the CD4 binding site (CD4bs) of the HIV-1 envelope are frequ...
The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the "principal neutrali...
<div><p>Primary isolates of HIV-1 resist neutralization by most antibodies to the CD4 binding site (...
Neutralizing antibodies that recognize the human immunodeficiency virus gpl20 exterior envelope glyc...
Epitopes that drive the initial autologous neutralizing antibody response in HIV-1-infected individu...
The early autologous neutralizing antibody response in human immunodeficiency virus type 1 (HIV-1) s...
The early autologous neutralizing antibody response in human immunodeficiency virus type 1 (HIV-1) s...